 The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mabs NASDAQ: IMAB IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors. The trial will evaluate enoblituzumab combined with Merck Co Incs NYSE: MRK Keytruda pembrolizumab in patients with selected solid tumors in China. 